SCHEMBL9067683

SCHEMBL9067683

C=COCCOP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
CDC25A P30304 2/20 0.54
AKT1 P31749 2/20 0.54
ESR1 P03372 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
AGTR1 P30556 1/20 0.54
ADRA1A P35348 1/20 0.54
KCNH2 Q12809 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PRKD3 O94806 1/20 0.43
PRKCG P05129 1/20 0.43
PRKCB P05771 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCH P24723 1/20 0.43
PRKCI P41743 1/20 0.43
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCZ Q05513 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20090040 0.83 LMNA (0.62) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL2118813 0.82 LMNA (0.53) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL170993 0.81 LMNA (0.56) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL1856364 0.80 LMNA (0.51) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL30874576 0.79 SMN1; SMN2 (0.51) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL139079 0.78 SMN1; SMN2 (0.49) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL29613185 0.77 LMNA (0.64) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL29613186 0.77 LMNA (0.64) LMNACDC25AAKT1ESR1ADORA3
SCHEMBL2118106 0.76 SMN1; SMN2 (0.48) LMNACDC25AAKT1ESR1ADORA3
Phosphocholine SCHEMBL10948480 0.76 SMN1; SMN2 (0.46) LMNACDC25AAKT1ESR1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121802-B1 HIGH REFRACTIVE INDEX SILOXANE INSERT MATERIALS FOR EMBEDDED CONTACT LENSES ALCON INC (CH) 2024-07-17 EP claimed
EP-4076916-B1 WETTABLE SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2024-06-12 EP claimed
EP-4369081-A2 METHOD FOR PRODUCING AN OPHTHALMIC PRODUCT Alcon Inc. (CH) 2024-05-15 EP claimed
EP-4121801-B1 INSERT MATERIALS WITH HIGH OXYGEN PERMEABILITY AND HIGH REFRACTIVE INDEX ALCON INC (CH) 2024-04-17 EP claimed
EP-4118134-B1 PHOTOCHROMIC POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS ALCON INC (CH) 2024-02-28 EP claimed
US-11867874-B2 Insert materials with high oxygen permeability and high refractive index ALCON INC. (CH) 2024-01-09 US claimed
WO-2023228055-A1 UV/HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-30 WO claimed
US-20230374306-A1 UV/HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-23 US claimed
US-20230364832-A1 METHOD FOR MAKING UV AND HEVL-ABSORBING OPHTHALMIC LENSES ALCON INC. (CH) 2023-11-16 US claimed
US-20230357478-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES ALCON INC. (CH) 2023-11-09 US claimed
US-10962803-B2 Contact lenses with a lubricious coating thereon ALCON INC. (CH) 2021-03-30 US claimed
EP-3774310-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2021-02-17 EP claimed
US-20200405747-A1 OPHTHALMIC COMPOSITIONS ALCON RESEARCH, LLC 2020-12-31 US claimed
WO-2020261185-A1 OPHTHALMIC COMPOSITIONS ALCON INC. (CH) 2020-12-30 WO claimed
US-20190300654-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON RESEARCH, LTD. 2019-10-03 US claimed
US-20190263971-A1 SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2019-08-29 US claimed
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI CO., LTD. (KR) 2014-09-25 US claimed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP claimed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US claimed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME C1QBP, PCTP, CD59 LMNA 1745/4885CDC25A 654/4885AKT1 3056/4885
US-20200405747-A1 OPHTHALMIC COMPOSITIONS B4GALT1, B3GAT3, ALG1 LMNA 1627/4885CDC25A 1260/4885AKT1 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.